Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma
29 nov. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany’s...
Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology
10 oct. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it is the first biotech company in Europe...
Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study
13 juin 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland and EVRY, France, June 13, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with...
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
23 mai 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, May 23, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in...
Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
16 févr. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces it has been...
Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
14 févr. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces that it has...
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
11 janv. 2023 02h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...